Aclarion Inc (ACON) Stock Price, Quote & News

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs whi...

Industry: Health Information Services

Sector: Healthcare

Phone: 833 275 2266

Website: www.aclarion.com

Address:

8181 Arista Place, Suite 100, Broomfield, United States

Stock_Catcher Jan. 14 at 2:47 AM

Wealthy Wednesday Watchlist Pt 10 $TMC $ACON $PAVS $ICU $IVF Let's Find another 950% Runner

1 · Reply

Donniechen12345 Jan. 14 at 1:37 AM

$ACON

0 · Reply

DonZulu Jan. 14 at 12:15 AM

$ACON 4.10 buying

0 · Reply

KuruHabesha Jan. 13 at 7:30 PM

$ACON Buy a high-potential stock at the lows and sleep like a baby.

0 · Reply

Surfratt Jan. 13 at 7:12 PM

$ACON ==========》》》

0 · Reply

silversg3006 Jan. 13 at 6:59 PM

$ACON I love the blocking capability on this app…..just glushed 1 of the bears!

0 · Reply

Donniechen12345 Jan. 13 at 6:41 PM

$ACON they will be ok $21.6 million , but not us stock holders , smh , the stock has no value now:( , unless they use that $12,000,000 scam offerring proceedings and buy back shares with it , otherwise this will keep trashing all week and months . :(((

0 · Reply

doubleyou2 Jan. 13 at 6:39 PM

$ACON It will be ok.

0 · Reply

Donniechen12345 Jan. 13 at 5:36 PM

$ACON they bettter start using that scam $12,000,000 dollars from that offering and rebuy shares with it or else this will trash to pennies terrorities very soon smh . will keep falling smh

1 · Reply

Apes_Strong Jan. 13 at 5:29 PM

$ACON new VP Vance fraud appointment will love what these guys have done

0 · Reply

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Oct 22, 2025, 6:00 AM EDT - 2 months ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 9, 2025, 6:00 AM EDT - 3 months ago

Aclarion to Present at the LD Micro Main Event XIX

Jun 24, 2025, 7:00 AM EDT - 7 months ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

May 20, 2025, 6:00 AM EDT - 8 months ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 8 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Apr 29, 2025, 6:00 AM EDT - 9 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 23, 2025, 6:00 AM EDT - 9 months ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 6:00 AM EDT - 9 months ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 9, 2025, 7:00 AM EDT - 9 months ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 2, 2025, 6:00 AM EDT - 10 months ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Mar 31, 2025, 7:00 AM EDT - 10 months ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 13, 2025, 9:25 AM EDT - 10 months ago

Aclarion Provides Shareholder Update

Mar 6, 2025, 9:35 AM EST - 11 months ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 3, 2025, 6:00 AM EST - 11 months ago

Aclarion Announces First Commercial Agreement with Scripps Health

Feb 20, 2025, 6:00 AM EST - 11 months ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 11, 2025, 7:58 AM EST - 1 year ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 6, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 4, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 6:57 AM EDT - 1 year ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 13, 2024, 8:30 AM EDT - 1 year ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 12, 2024, 6:57 AM EDT - 1 year ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 10, 2024, 6:57 AM EDT - 1 year ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 5, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aug 29, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 21, 2024, 7:57 AM EDT - 1 year ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 15, 2024, 9:48 AM EDT - 1 year ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 8:08 AM EDT - 1 year ago

Aclarion Announces First Commercial Agreement in Michigan

Aug 13, 2024, 9:07 AM EDT - 1 year ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 1 year ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Feb 27, 2024, 3:22 PM EST - 2 years ago

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 2 years ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 5, 2024, 8:00 AM EST - 2 years ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 6, 2023, 8:00 AM EST - 2 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 24, 2023, 8:45 AM EDT - 2 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aug 25, 2023, 4:10 PM EDT - 2 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Jun 14, 2023, 11:27 AM EDT - 2 years ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 8, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 23, 2023, 7:30 AM EDT - 2 years ago

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Stock_Catcher Jan. 14 at 2:47 AM

Wealthy Wednesday Watchlist Pt 10 $TMC $ACON $PAVS $ICU $IVF Let's Find another 950% Runner

1 · Reply

Donniechen12345 Jan. 14 at 1:37 AM

$ACON

0 · Reply

DonZulu Jan. 14 at 12:15 AM

$ACON 4.10 buying

0 · Reply

KuruHabesha Jan. 13 at 7:30 PM

$ACON Buy a high-potential stock at the lows and sleep like a baby.

0 · Reply

Surfratt Jan. 13 at 7:12 PM

$ACON ==========》》》

0 · Reply

silversg3006 Jan. 13 at 6:59 PM

$ACON I love the blocking capability on this app…..just glushed 1 of the bears!

0 · Reply

Donniechen12345 Jan. 13 at 6:41 PM

0 · Reply

doubleyou2 Jan. 13 at 6:39 PM

$ACON It will be ok.

0 · Reply

Donniechen12345 Jan. 13 at 5:36 PM

$ACON they bettter start using that scam $12,000,000 dollars from that offering and rebuy shares with it or else this will trash to pennies terrorities very soon smh . will keep falling smh

1 · Reply

Apes_Strong Jan. 13 at 5:29 PM

$ACON new VP Vance fraud appointment will love what these guys have done

0 · Reply

1_ofThe_orig_Moonboyz Jan. 13 at 5:23 PM

$ACON If it’s not above my average by the time they play the bills Denver will not win because I’ll be thinking bills

0 · Reply

Apes_Strong Jan. 13 at 5:21 PM

$ACON 2,850,000

1 · Reply

1_ofThe_orig_Moonboyz Jan. 13 at 5:16 PM

$ACON Need to get this going like the Broncos just like BDSX. Both are within 30 miles from the stadium

0 · Reply

Huskersnsaints Jan. 13 at 5:16 PM

$ACON at least i own this a a 52 week low pretty normal for me on any stock i purchase it immediately tanks Its a gift

0 · Reply

hmmmuhhh Jan. 13 at 5:08 PM

$ACON how many outstanding shares?

0 · Reply

Donniechen12345 Jan. 13 at 5:04 PM

$ACON lol they said they boost balanced sheet ( $12,000,000 for vacation and bonus times ). they dont need$$$ and dilute raise offering , they have money$$$$$$ and zero debt !!!!!!!!!’ wtf man . EPIC ponzi scamm !!!! smh

0 · Reply

doubleyou2 Jan. 13 at 5:01 PM

$ACON 222 bitcoins 😁🙃

0 · Reply

isa_32 Jan. 13 at 4:55 PM

$ACON 🔥

0 · Reply

isa_32 Jan. 13 at 4:55 PM

$ACON 🔥

0 · Reply

Apes_Strong Jan. 13 at 4:27 PM

$ACON Brent Ness, Chief Executive Officer of Aclarion, stated, “With a debt-free balance sheet, strong cash reserves, and extended cash runway into 2028, we are focused [on tripling our salaries to fuck all shareholders and orchestrate as many market manipulations as possible to ensure our personal survival without regard for dilution] squarely on execution, expanding adoption of Nociscan, deepening clinical evidence, and building strategic relationships that drive durable growth for patients, providers, payers, and shareholders.”

2 · Reply

modrica3 Jan. 13 at 4:26 PM

$ACON they all do that , behind closed doors they make deal and tell those bastards they will pump the stock to short it up and then use shares in offering to just simply return them and use them against shorting , youre right and its hard to trace it

1 · Reply

Donniechen12345 Jan. 13 at 4:23 PM

$ACON

0 · Reply

Market Cap	3.03M
Revenue (ttm)	50,000.00
Net Income (ttm)	-6.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,980.00%
Debt to Equity Ratio	0.00

Volume	721,100
Avg Vol	997,840
Day's Range	N/A - N/A
Shares Out	671,000.00
Stochastic %K	3%
Beta	1.44
Analysts	Sell
Price Target	$23.00